Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29981309 | 1.00 | MGLL (0.35) | MGLLABHD6BRD4CREBBPBUB1 | |
| SCHEMBL20700434 | 1.00 | MGLL (0.35) | MGLLABHD6BRD4CREBBPBUB1 | |
| SCHEMBL20699928 | 1.00 | MGLL (0.35) | MGLLABHD6BRD4CREBBPBUB1 | |
| SCHEMBL20700569 | 0.95 | MGLL (0.35) | MGLLABHD6BRD4CREBBPBUB1 | |
| SCHEMBL20718693 | 0.91 | ADRA2A (0.38) | PTGDRSCN9AKCNH2SCN5AGPR119 | |
| SCHEMBL20699938 | 0.91 | GPR119 (0.34) | BRD4CREBBPPTGDRGPR119UCHL1 | |
| SCHEMBL20700711 | 0.91 | GPR119 (0.34) | BRD4CREBBPPTGDRGPR119UCHL1 | |
| SCHEMBL29981344 | 0.91 | GPR119 (0.34) | BRD4CREBBPPTGDRGPR119UCHL1 | |
| SCHEMBL20699941 | 0.91 | GPR119 (0.34) | BRD4CREBBPPTGDRGPR119UCHL1 | |
| SCHEMBL20700156 | 0.90 | ADRA2A (0.37) | MGLLABHD6BRD4CREBBPBUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3661929-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | MGLL 2310/4885ABHD6 2023/4885BRD4 3128/4885 |
| US-10780074-B2 | Compounds and uses thereof | PYGB, NLN, MAOB | MGLL 2310/4885ABHD6 2023/4885BRD4 3128/4885 |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | MGLL 2310/4885ABHD6 2023/4885BRD4 3128/4885 |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | GRIN2C, INA, SDHA | MGLL 1749/4885ABHD6 1885/4885BRD4 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.